Leukotriene B4 Ethanolamide (LTB4-EA) is primarily studied for its role in modulating inflammatory responses. It is known to interact with specific receptors involved in immune regulation, making it a potential target for research in inflammatory diseases such as arthritis, asthma, and psoriasis. Its ability to influence leukocyte activity and cytokine production suggests applications in developing therapies for conditions characterized by excessive inflammation. Additionally, LTB4-EA is being explored for its potential in neuroinflammation studies, particularly in diseases like multiple sclerosis and Alzheimer’s, where inflammatory pathways play a critical role. Ongoing research also investigates its utility in cancer immunotherapy, as it may help modulate the tumor microenvironment by affecting immune cell behavior.